European Journal of Heart Failure Advance Access originally published online on May 20, 2009
European Journal of Heart Failure 2009 11(7):728; doi:10.1093/eurjhf/hfp067
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
Immunological mechanisms of pentoxifylline in chronic heart failure
Department of Nephrology
Tel Aviv Medical Center, Weizman 6
Tel Aviv 64239, Israel
Email: donald@netvision.net.il
Department of Cardiology/Heart Failure Unit
Tel Aviv Medical Center, Weizman 6
Tel Aviv 64239, Israel
Department of Nephrology
Tel Aviv Medical Center, Weizman 6
Tel Aviv 64239, Israel
Department of Nephrology
Tel Aviv Medical Center, Weizman 6
Tel Aviv 64239, Israel
| The first 10% of the full text of this article appears below. |
Dear Editor
In the recent summary of the effects of pentoxifylline (PTX) in chronic heart failure (CHF), Shaw et al.1 review several